---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-23-014355"
form_type: "8-K"
ticker: "NDRA"
cik: "0001681682"
company_name: "ENDRA Life Sciences Inc."
filed_at: "2023-11-14T23:59:59+00:00"
generated_at: "2026-06-08T03:45:08.343097+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# ENDRA Life Sciences Q3 net loss $3.1M; FDA De Novo review ongoing

## Summary
- Net loss $3.1M ($0.40/share) vs $3.4M ($1.09/share) in Q3 2022; operating expense $3.1M.
- Cash $3.3M at Sept 30; raised $1.2M via ATM equity facility during Q3.
- TAEUS De Novo submission under substantive FDA review; clinical data showed 95% sensitivity.
- Achieved 70 issued patents globally; targeting first European commercial orders near-term.
- Presented at major liver disease conferences; expects MASLD treatment approvals in early 2024.

## SEC filing metadata
- accession: 0001654954-23-014355
- form_type: 8-K
- ticker: NDRA
- cik: 0001681682
- company_name: ENDRA Life Sciences Inc.
- filed_at: 2023-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1681682/000165495423014355/0001654954-23-014355-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1681682/000165495423014355/ndra_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-23-014355
- JSON: https://secwatch.observer/filing/0001654954-23-014355.json
- Plain text: https://secwatch.observer/filing/0001654954-23-014355.txt

## Key facts
- Earnings Releases
  ENDRA Life Sciences Inc. reported the quarter ended September 30, 2023 results: net income Net loss in the third quarter of 2023 was $3.1 million, or $0.40 per share, EPS $0.40 per share.
  - Period: the quarter ended September 30, 2023
  - Net income: Net loss in the third quarter of 2023 was $3.1 million, or $0.40 per share
  - EPS: $0.40 per share
  - Result: reported results
  source text: ENDRA Life Sciences Inc . (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), today reports financial results for the three and nine months ended September 30, 2023 and provides a business update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1681682/000165495423014355/0001654954-23-014355-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.